Cantor Fitzgerald Initiates Coverage on EIKN (NASDAQ:EIKN)

Stock analysts at Cantor Fitzgerald began coverage on shares of EIKN (NASDAQ:EIKN) in a note issued to investors on Monday, MarketBeat Ratings reports. The firm set an “overweight” rating on the stock.

EIKN has been the subject of several other research reports. Mizuho started coverage on shares of EIKN in a research report on Monday. They set an “outperform” rating and a $26.00 target price for the company. Wedbush began coverage on EIKN in a research note on Thursday, February 26th. They set an “underperform” rating and a $7.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on EIKN in a research note on Monday. They issued an “overweight” rating and a $29.00 target price on the stock. Morgan Stanley started coverage on EIKN in a report on Monday. They set an “overweight” rating and a $32.00 target price on the stock. Finally, Bank of America initiated coverage on EIKN in a research report on Monday. They set a “buy” rating and a $34.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Stock Down 7.3%

EIKN opened at $13.80 on Monday. EIKN has a fifty-two week low of $13.28 and a fifty-two week high of $17.40.

More EIKN News

Here are the key news stories impacting EIKN this week:

• Positive Sentiment: Multiple major brokerages initiated coverage with bullish ratings and high price targets — Morgan Stanley started coverage with an “overweight” and $32 PT. Article Title
• Positive Sentiment: Bank of America initiated coverage with a “buy” rating and a $34 price target (largest upside among the reported PTs). Article Title
• Positive Sentiment: JPMorgan also initiated coverage with an “overweight” rating and a $29 price target. Article Title
• Positive Sentiment: Mizuho started coverage with an “outperform” rating and a $26 price target. Article Title
• Positive Sentiment: Cantor Fitzgerald added coverage with an “overweight” rating as well, adding to the cluster of institutional bullish views. Article Title
• Neutral Sentiment: Reported short‑interest figures are inconsistent/likely erroneous (entries show 0 shares and NaN changes, with a days‑to‑cover of 0.0), so short‑squeeze or large short‑covering dynamics are not substantiated by the available data.
• Negative Sentiment: Despite the bullish analyst activity, shares moved lower on light trading (reported intraday volume ~144k vs. average ~403k) and trade near the 12‑month low region (~$13.28 low, $17.40 high), suggesting limited buying follow‑through and possible near‑term profit‑taking or broader market pressure.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.